India, July 30 -- The Indian drug makers have spent the past few years to get rid of the tag they have never liked much - being domestic, generic, and low margin. The big firms have gone after specialty drugs and exports, hoping that real price power lies there. It seems RPG Life Sciences is following a similar approach.

With a market capitalisation of Rs. 4,610.25 crore, the shares of RPG Life Sciences closed on Thursday at Rs. 2,778.10, down 2.53 percent from the previous close of Rs. 2,850.20, and it is trading at a P/E of 39.40.

Building an Immunosuppressant Moat The aim is to build the immunosuppressive line into a business larger than Rs. 200 crore. Presently, RPG sells Azathioprine, Cyclosporine, Tacrolimus, and Mycophenolate Mof...